Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: An increasing problem

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Al Jasser, Asma Marzouq ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; CYTOTOXIC AGENT; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NORFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIMENTIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLADDER CARCINOMA; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DEATH; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PUBLIC HOSPITAL; SAUDI ARABIA; SEPTIC SHOCK; STENOTROPHOMONAS MALTOPHILIA;

AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FATAL OUTCOME; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; SAUDI ARABIA; SHOCK, SEPTIC; STENOTROPHOMONAS MALTOPHILIA; SULFAMETHOXAZOLE; TREATMENT OUTCOME; TRIMETHOPRIM;

EID: 33749341590     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-23     Document Type: Article

References (16)

1. Lennett EH, Baburs A, Hausler WJ, Shadomy HJ: Manual of Clinical Microbiology. 9th edition. Washington DC: American Society for Microbiology.
2. Koseoglu O, Sener B, Gulmez D, Altun B, Gur D: Stenotrophomonas maltophilia as a nosocomial pathogen. New Microbiol 2004, 27:273-279.
3. Denton M, Kerr KG: Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998, 11:57-80.
4. Micozzi A, Venditti M, Monaco M, Friedrich A, Taglietti F, Santilli S, Martino P: Bacteremia due to Stenotrophomonas maltophilia in patients with hematological malignancies. Clin Infect Dis 2000, 31:705-711.
5. Tsiodras S, Pittet D, Carmeli Y, Eliopoulos G, Boucher H, Harbath S: Clinical implications of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: a study of 69 patients at 2 university hospitals. Scand J Infect Dis 2000, 32:651-656.
6. Smit WJ, Boquest AL, Geddes JE, Tosolini FA: The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management. Pathology 1994, 26:321-324.
7. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K: A changing pattern of susceptibility of Xanthomonas maltophilia; implications for therapy. Antimicrob Agents Chemother 1994, 38:624-627.
8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing 15th informational supplement (M 100-S15). National Committee for Clinical Laboratory Standards Wayne Pa 2005.
9. Pankuch GA, Jacobs MR, Rittenhouse SF, Appelbaum PC: Susceptibilities of 123 strains of Xanthomonas moltophilia to eight Blactams (including B-lactam-B-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother 1994, 38:2317-2322.
10. Gales AC, Jones RN, Forward KR, Linares J, Sader HS, Verhoef J: Emerging importance of multi-drug resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in severely ill patients: geographic patterns, epidemiological features and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis 2001, 32:104-113.
11. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L: Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004, 28:168-171.
12. Weiss K, Restieri C, De Carolis E, Laverdiere M, Guay H: Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000, 45:363-365.
13. Giamarellos-Bourboulis EJ, Kamesis L, Galani I, Giamarellou H: In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 2002, 46:3997-3999.
14. Felegie TP, Yu VL, Ruwans LW, Yee RB: Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination. Antimicrob Agents Chemother 1979, 16:833-837.
15. Chow AW, Wong J, Bartlett KH: Synergistic interactions of ciprofloxacin and extended spectrum beta - lactams or aminoglycosides against multiple drug resistant Pseudomonas maltophilia. Antimicrob Agents Chemother 1988, 32:782-784.
16. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H: Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multi-drug resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2002, 44:259-263.